ClinicalTrials.gg
RecruitingNCT07656857Epi-PRECISEUpdated Aug 13, 2026

High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT

An interventional study of Using High-density Flexible microElectrocorticography for intraoperative monitoring in Focal Epilepsy and Intraoperative Monitoring, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 3 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
3 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsies, Partial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Epilepsies, Partial · China.

Started
2026
the only one that year
No phase
3 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Beijing Tiantan Hospital

Among the 10 studies in Epilepsies, Partial with a site in China, this one is the only one that started in 2026, is one of 3 with no phase, and was the 9th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

6 of the 10 studies in Epilepsies, Partial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 3 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsies, Partial with a site in China, or all of them as a file.
02

Study summary

What's the clinical value of high-density flexible microelectrocorticography (μECoG) for guiding the resection of epileptogenic zone (EZ) in epilepsy surgery?

Read the detailed description
  1. Compare the effect of intraoperative high-density flexible μECoG guidance versus no intraoperative μECoG guidance on surgical prognosis in patients with drug-resistant focal epilepsy.
  2. Explore intraoperative electrophysiological biomarkers recorded by high-density μECoG that are associated with surgical prognosis.
03

Conditions studied

  • Focal Epilepsy
  • Intraoperative Monitoring

Browse trials for

Keywords

  • Epilepsy surgery
  • microelectrocorticography (μECoG)
04

Who can participate

Ages eligible
3 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 3 to 60 years.
  2. Diagnosis of drug-resistant epilepsy, defined as persistent seizures despite treatment with two or more appropriately selected, adequately dosed and adequately tried antiseizure medications.
  3. Diagnosis of focal epilepsy after standard presurgical evaluation and considered suitable for resective epilepsy surgery.
  4. Preoperative cognitive or developmental status sufficient to participate in study assessments, as judged by the investigator and assessed using age-appropriate validated instruments. For participants aged 3 to 6 years, developmental status must be within the normal range according to the Griffiths Mental Development Scales. For participants aged 6 to 16 years, cognitive function must be within the normal range according to the Wechsler Intelligence Scale for Children. For participants older than 16 years, a score of 24 or higher will be required.
  5. Written provided by the participant or, when applicable, by a legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Suspected mesial temporal lobe epilepsy after multidisciplinary presurgical evaluation.
  2. History of any previous neurosurgical craniotomy before epilepsy surgery.
  3. Severe psychiatric, cognitive, or psychological disorder that prevents participation in the study or completion of follow-up.
  4. to surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Intraoperative application of high-density flexible μECoG-Guided Resection

    Device: Using High-density Flexible microElectrocorticography for intraoperative monitoring

Interventions

  • DeviceUsing High-density Flexible microElectrocorticography for intraoperative monitoring

    During resective epilepsy surgery, a sterile high-density flexible microelectrocorticography will be placed on the exposed cortical surface over the suspected epileptogenic zone and adjacent cortex. The array will be used for high-spatial-resolution intraoperative μECoG recording and real-time analysis of epileptiform activity, including interictal spikes, high-frequency oscillations, spatial discharge gradients, and propagation patterns. The intraoperative ECoG findings will be provided to the surgical team to assist in defining the epileptogenic zone and tailoring the extent of resection. The high-density μECoG is used for intraoperative recording only and will be removed before wound closure.

06

What researchers measure

Primary outcomes

  1. Seizure Freedom Rate at 6 Months After Surgery

    The proportion of participants who remain free from any type of epileptic seizure during the 6-month postoperative follow-up period.

    Time frame: From surgery to 6 months postoperatively

Secondary outcomes

  1. Seizure Freedom Rate at 1 Year After Surgery

    The proportion of participants who remain free from any type of epileptic seizure during the 1-year postoperative follow-up period.

    Time frame: From surgery to 1 year postoperatively

  2. Postoperative Seizure Outcome According to ILAE Classification

    Postoperative seizure outcome will be evaluated using the International League Against Epilepsy classification at 6 months and 1 year after surgery. ILAE class 1 indicates complete seizure freedom without aura, and higher classes indicate worse seizure outcomes.

    Time frame: 6 months and 1 year postoperatively

  3. Monthly Seizure Frequency

    Monthly seizure frequency will be assessed before surgery and at 6 months and 1 year after surgery. The measure is defined as the average number of epileptic seizures per month.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  4. Seizure Severity Assessed by the National Hospital Seizure Severity Scale

    Seizure severity will be assessed using the National Hospital Seizure Severity Scale (NHS3) before surgery and at 6 months and 1 year after surgery. The NHS3 is a seizure severity scale with scores ranging from 1 to 27, with higher scores indicating more severe seizures and therefore a worse outcome.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  5. Developmental Function Assessed by the Griffiths Mental Development Scales

    For participants aged 3 to 6 years, developmental function will be evaluated using the Griffiths Mental Development Scales before surgery and at 6 months and 1 year after surgery. The primary reported score will be the General Developmental Quotient or General Quotient. The quotient score ranges from 50 to 150, with higher scores indicating better developmental function and therefore a better outcome.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  6. Cognitive Function Assessed by the Wechsler Intelligence Scale for Children

    For participants aged 6 to 16 years, cognitive function will be evaluated using the Wechsler Intelligence Scale for Children before surgery and at 6 months and 1 year after surgery. The primary reported score will be the Full Scale Intelligence Quotient. The Full Scale Intelligence Quotient standard score ranges from 40 to 160, with higher scores indicating better cognitive function and therefore a better outcome.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  7. Cognitive Function Assessed by the Mini-Mental State Examination

    For participants older than 16 years, cognitive function will be evaluated using the Mini-Mental State Examination (MMSE) before surgery and at 6 months and 1 year after surgery. The MMSE total score ranges from 0 to 30, with higher scores indicating better cognitive function and therefore a better outcome.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  8. Quality of Life Assessed by the Quality of Life in Epilepsy Inventory-31 or the Pediatric Quality of Life Inventory Version 4.0

    Quality of life will be evaluated before surgery and at 6 months and 1 year after surgery. Adult participants will be assessed using the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), and pediatric participants will be assessed using the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0). Both scales are transformed to scores ranging from 0 to 100, with higher scores indicating better quality of life and therefore a better outcome.

    Time frame: Baseline, 6 months postoperatively, and 1 year postoperatively

  9. Postoperative Complications

    The incidence of postoperative complications, including infection, fever, neurological deficits, and other surgery-related complications, will be recorded during the perioperative period and postoperative follow-up.

    Time frame: Perioperative period, 6 months postoperatively, and 1 year postoperatively

  10. Surgery-Related Adverse Events

    The incidence of surgery-related adverse events will be recorded during the perioperative period. Adverse events include events directly related to the surgical procedure.

    Time frame: Perioperative period

  11. Serious Adverse Events

    The incidence of serious adverse events, including postoperative death or severe deterioration of health status during the perioperative period, will be recorded.

    Time frame: Perioperative period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Xingjian Liu, Chao Zhang, Baotian Zhao, et al., Preliminary application study of flexible high-density cortical electrodes in assisting localization of epileptogenic zones during epileptogenic zonectomy, Chinese Journal of Neurosurgery, 2025, 41(12):1237-1244. DOI:10.3760/cma.j.cn112050-20250919-00362
  • Guo J, Wang Z, van 't Klooster MA, Van Der Salm SM, Leijten FS, Braun KP, Zijlmans M. Seizure Outcome After Intraoperative Electrocorticography-Tailored Epilepsy Surgery: A Systematic Review and Meta-Analysis. Neurology. 2024 Jun 11;102(11):e209430. doi: 10.1212/WNL.0000000000209430. Epub 2024 May 20. PubMed 38768406 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 18, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656857
Collaborators
Beijing Fengtai Hospital, Peking University First Hospital, The Chinese University of Hong Kong, Shenzhen, Beijing Xinzhida Neural Technology Co., Ltd, Beijing Neurosurgical Institute
Responsible party
Kai Zhang (Director of the Department of Neurosurgery, Clinical Professor, Beijing Neurosurgical Institute) — Principal investigator
First posted
Jun 18, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Kai Zhang Dr
Contact
zhangkai62035@sina.com
86 01059975051

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion